New Hope for Fighting Influenza with Near Infrared Antiviral Photoimmunotherapy

Medical News: A Revolutionary Approach to Combat Influenza
Scientists have developed a promising new way to fight the influenza virus using near-infrared antiviral photoimmunotherapy (NIR-AVPIT). This groundbreaking treatment, developed by researchers from Medical Corporation Koujunkai, Tokai University School of Medicine, and the Genome Medical Sciences Project at the National Center for Global Health and Medicine in Japan, targets and destroys both the influenza virus and the infected cells using a combination of light therapy and antibodies.


New Hope for Fighting Influenza with Near Infrared Antiviral Photoimmunotherapy

Influenza remains a significant global health concern, infecting millions every year and causing severe illness and death. Existing antiviral medications often lose their effectiveness due to viral mutations, making it crucial to find alternative therapies. This Medical News report highlights a new strategy that could revolutionize how we treat influenza infections.
 
How Does Near Infrared Antiviral Photoimmunotherapy Work
NIR-AVPIT is based on an advanced cancer treatment method known as near-infrared photoimmunotherapy (NIR-PIT). The therapy involves using a special antibody that attaches to the virus or infected cells. This antibody is linked to a light-sensitive dye called IR700. When exposed to near-infrared light, the dye becomes activated, triggering a reaction that damages and kills the targeted cells without harming healthy cells.
 
For this study, the researchers focused on the influenza A (H1N1)pdm09 virus, the same strain responsible for the 2009 pandemic. They designed a monoclonal antibody that binds specifically to hemagglutinin (HA), a key protein found on the surface of the virus. However, unlike traditional antibodies that neutralize the virus, this one does not block infection on its own. Instead, it works in conjunction with near-infrared light to destroy the virus and infected cells.
 
Key Findings of the Study
The researchers conducted a series of laboratory experiments to evaluate how effective NIR-AVPIT is in combating the influenza virus. Their findings revealed several crucial points:
 
-Direct Inactivation of Influenza Virus: The treatment significantly reduced the viral load when the virus was exposed to the antibody and near-infrared light. This suggests that the therapy can directly destroy free-floating viral particles before they infect cells.
 
-Elimination of Infected Cells: Cells infected with the virus were effectively destroyed when treated with NIR-AVPIT. This is important because it prevents the virus from replicating and spreading further.
 
-Timing Matters: The therapy was most effective when applied early in the infection process. Treatment at seven hours post-infection significantly reduced viral spread, whereas treatment at later stages was less effective. This suggests that early intervention is crucial for maximum effect iveness.
 
-Repeated Treatment Boosts Effectiveness: Administering the therapy twice, at different time points, resulted in a greater reduction in viral activity compared to a single treatment. This indicates that multiple treatments may be necessary for optimal results.
 
-Selective Targeting of Infected Cells: The study confirmed that the therapy specifically targets virus-infected cells while leaving healthy cells unharmed, reducing the risk of side effects.
 
Why This Study is Important
The findings offer hope for a new kind of antiviral treatment that does not rely on traditional drugs. Many current antiviral medications, such as neuraminidase inhibitors and RNA polymerase inhibitors, have limitations, including the risk of drug resistance and a narrow window for effectiveness. NIR-AVPIT offers a novel approach that directly destroys the virus, rather than simply slowing its replication.
 
Additionally, this therapy could be used in combination with existing treatments to improve outcomes, especially for high-risk populations such as the elderly and individuals with underlying health conditions. Unlike vaccines, which require time for the immune system to build protection, this therapy offers a fast-acting solution that can work immediately upon infection.
 
Challenges and Future Directions
While the study results are promising, there are several challenges that must be addressed before NIR-AVPIT can be used in clinical settings. One major hurdle is the need for a specialized device to administer the near-infrared light therapy. Unlike oral antiviral medications, this treatment requires controlled light exposure, which may not be easily accessible for home use.
 
Another consideration is the effectiveness of the therapy against different strains of the influenza virus. The researchers targeted hemagglutinin, which varies between strains. Future studies will need to determine whether a broad-spectrum antibody can be developed to target multiple influenza variants.
 
The research team also suggests that the therapy might have applications beyond influenza. Other viral infections that involve surface antigens, such as coronaviruses and herpes viruses, may also be suitable targets for NIR-AVPIT.
 
Further studies are required to explore the full potential of this approach in treating a wide range of viral infections.
 
Conclusion
Near-infrared antiviral photoimmunotherapy presents a groundbreaking approach to treating influenza by directly targeting both the virus and infected cells. The study demonstrated that this treatment effectively inactivates free virus particles, eliminates infected cells, and prevents further viral spread, especially when administered early in the infection process. The research also highlighted the importance of repeated treatment for enhanced effectiveness. While challenges remain in terms of accessibility and broader applicability, this therapy has the potential to revolutionize the way we manage viral infections. Future research will determine how this promising technique can be adapted for widespread use in clinical practice.
 
The study findings were published in the peer-reviewed journal: Pharmaceutics.
https://www.mdpi.com/1999-4923/17/2/173
 
For the latest on Influenza, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/alkylamides-from-echinacea-shows-promising-effects-against-respiratory-viruses
 
https://www.thailandmedical.news/news/promising-hope-from-sturgeon-oil-for-respiratory-health
 
https://www.thailandmedical.news/news/traditional-chinese-medicine-breakthrough-qi-pi-pill-shows-promise-against-influenza
 
https://www.thailandmedical.news/articles/influenza-or-flu
 
https://www.thailandmedical.news/articles/h5n1-avian-flu